Cogent Biosciences Inc. — Sponsor Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

1 Recruiting

2 Completed trials

15 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

3 total

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting

2022-501427-24-00 Phase II 12 countries 3,4-DIMETHYL-N-(2-PHENYL-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLE-5-CARBOXAMID…
(Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended

2022-500637-80-00 Phase III 11 countries 3,4-DIMETHYL-N-(2-PHENYL-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLE-5-CARBOXAMID…
A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy… Ended

2024-511407-42-00 Phase II 9 countries 3,4-DIMETHYL-N-(2-PHENYL-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-1H-PYRAZOLE-5-CARBOXAMID…

Showing 1–3 of 3 trials